683 Capital Management’s Compass Therapeutics CMPX Stock Holding History

683 Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-38,039	Closed	-$124K	–	192
2023 Q1	$124K	Hold	38,039	–	–	0.01%	222
2022 Q4	$191K	Buy	+38,039	New	+$152K	0.02%	174

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

683 Capital Management's CMPX Position: Q2 2023 in Review

683 Capital Management sold out of Compass Therapeutics (CMPX) in Q2 2023, closing a stake of 38,039 shares — an estimated $124K sold.

683 Capital Management first reported a position in CMPX in Q4 2022 and held it in 2 quarters. The position peaked at $191K in Q4 2022. 73 funds tracked by Wall St. Rank hold CMPX as of Q2 2023.

683 Capital Management reported no remaining Compass Therapeutics position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 38,039 Compass Therapeutics shares in Q2 2023, an estimated $124K.
683 Capital Management first reported a position in Compass Therapeutics in Q4 2022 and held it in 2 quarters.
683 Capital Management's Compass Therapeutics position peaked at $191K in Q4 2022.
73 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.